Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 and/or Gilteritinib in Newly Diagnosed AML
NCT04293562Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jul 2020
- Primary completion
- Jun 2029
- Modality
- Fragment-Derived Small Molecules, Targeted Liposomes, Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of daunorubicin + cytarabine liposome and gilteritinib in acute myeloid leukemia (AML), sponsored by Children's Oncology Group. Started Jul 2020; status: recruiting.
02
Drugs
daunorubicin + cytarabine liposomegilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04293562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04293562.